3,000,000 Shares in Esperion Therapeutics, Inc. $ESPR Bought by AIGH Capital Management LLC

AIGH Capital Management LLC purchased a new position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,000,000 shares of the biopharmaceutical company’s stock, valued at approximately $7,950,000. Esperion Therapeutics makes up approximately 2.2% of AIGH Capital Management LLC’s portfolio, making the stock its 17th biggest holding. AIGH Capital Management LLC owned 1.49% of Esperion Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ESPR. The Manufacturers Life Insurance Company increased its stake in Esperion Therapeutics by 7.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 72,705 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 4,979 shares in the last quarter. CWM LLC lifted its stake in Esperion Therapeutics by 46.5% in the third quarter. CWM LLC now owns 19,674 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 6,249 shares in the last quarter. DHJJ Financial Advisors Ltd. boosted its holdings in shares of Esperion Therapeutics by 209.2% in the third quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 6,380 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in shares of Esperion Therapeutics by 54.1% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 23,916 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 8,394 shares in the last quarter. Finally, North Star Investment Management Corp. increased its position in shares of Esperion Therapeutics by 40.0% during the third quarter. North Star Investment Management Corp. now owns 35,000 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 10,000 shares in the last quarter. Institutional investors own 47.39% of the company’s stock.

Insider Buying and Selling at Esperion Therapeutics

In other news, CFO Benjamin Halladay sold 7,337 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total value of $26,926.79. Following the sale, the chief financial officer directly owned 467,525 shares of the company’s stock, valued at approximately $1,715,816.75. This represents a 1.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders have sold 15,543 shares of company stock worth $55,709. 1.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Citigroup reaffirmed a “market outperform” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. Finally, Piper Sandler started coverage on Esperion Therapeutics in a research note on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.20.

Esperion Therapeutics Stock Down 0.9%

ESPR stock opened at $3.14 on Friday. The company has a market cap of $750.65 million, a price-to-earnings ratio of -6.28, a P/E/G ratio of 6.47 and a beta of 1.04. Esperion Therapeutics, Inc. has a twelve month low of $0.69 and a twelve month high of $4.18. The business has a 50 day moving average price of $3.59 and a two-hundred day moving average price of $2.74.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.07). The company had revenue of $87.31 million for the quarter, compared to analyst estimates of $78.33 million. On average, equities research analysts anticipate that Esperion Therapeutics, Inc. will post -0.29 EPS for the current fiscal year.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.